

November 07, 2025

To,
Listing Department,
The BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400001.

Scrip Code: 540737

Dear Sir(s)/Ma'am,

Sub: Press Release

With reference to the captioned subject, we enclose herewith the Press Release with respect to Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025.

Kindly take the same on your record.

Thanking You,

Yours faithfully,

For Shree Ganesh Remedies Limited

Aditya Patel
Company Secretary and Compliance Officer

Enc. a/a

SHREE GANESH REMEDIES LIMITED REPORTS Q2 & H1FY26 RESULTS

Ankleshwar, November 7th, 2025: Shree Ganesh Remedies Limited, one of the fastest growing CMO & CDMO based in India for Pharmaceutical Intermediates & Fine Chemicals, announced its financial results for Q2 & H1FY26.

Commenting on the results, Mr. Gunjan Kothia, Promoter, Head of Business Development & Innovation, said:

"In line with our expectations, SGRL delivered sequential growth in Q2FY26, reflecting the company's historically stronger performance in this quarter. The quarter-on-quarter improvement was driven by higher volumes and steady execution across key client projects. On a year-on-year basis, however, sales remained subdued due to lower realisations in the domestic market and softened demand across Europe.

As previously guided, our margins continued to moderate with the repricing of contracts within the CRAMS business. We remain focused on optimising our product mix to sustain profitability amid these evolving dynamics. Despite muted realisations and the impact of higher depreciation and finance costs arising from recent capital investments, our profitability remained resilient. We continue to remain confident of sustaining our EBITDA margins in the range of 24–26% over the long term.

Operationally, we have made substantial progress on the new pilot facility, which has now reached the final stages of commissioning. Completion is expected in Q3FY26, with operations scheduled to commence in Q4FY26. Work on Block 7 is progressing as planned, with the plant expected to be operational and begin commercial production in H2FY27.

The newly commissioned Block 8 also showed encouraging trends with rising capacity utilisation through the quarter. We aim to achieve 50–60% utilisation by the end of the current financial year.

On the business development front, we received approval from a European client for a new agrochemical project, with commercial orders scheduled to begin by Q4FY27. In Europe, we also secured a significant engagement with a leading pharmaceutical company. Progress with our Japanese client on the specialty chemicals project continues positively, and we expect to receive final project approvals by mid-2026. Additionally, we are actively evaluating new opportunities in European and Japanese market.

Overall, we continue to strengthen our infrastructure and innovation capabilities. As guided earlier, FY26 remains a year of consolidation and capability-building, laying a strong foundation for scale-up and accelerated growth in the years ahead."

Financial Highlights for Quarter Ended September 30th, 2025:

(₹ In crore & %)

REVENUE
30.32 Cr.
⬇️ -6% YoY

EBITDA
9.62 Cr.
⬇️ -15% YoY

PAT
4.93 Cr.
⬇️ -23% YoY

EBITDA MARGINS
31.7 %
⬇️ -325 BPS YoY

19.15 Cr.
Revenue from Pharma
Intermediates in Q2FY26

11.17 Cr.
Revenue from
Speciality Chemicals
in Q2FY26

17.30 Cr.*
Revenue from
Exports in Q2FY26

12.79 Cr.*
Revenue from
Domestic Sales
in Q2FY26

Financial Highlights for Half Year Ended September 30th, 2025:

(₹ In crore & %)

REVENUE
54.98 Cr.
⬇️ -4% YoY

EBITDA
16.92 Cr.
⬇️ -13% YoY

PAT
8.37 Cr.
⬇️ -24% YoY

EBITDA MARGINS
30.8 %
⬇️ -326 BPS YoY

32.64 Cr.
Revenue from Pharma
Intermediates in H1FY26

22.34 Cr.
Revenue from
Speciality Chemicals
in H1FY26

28.37 Cr.*
Revenue from
Exports in H1FY26

26.26 Cr.*
Revenue from
Domestic Sales
in H1FY26

*Revenue excluding other operating income

Financial Highlights:

PARTICULARS (₹ IN CRORES)	Q2FY25	Q1FY26	Q2FY26	YoY Change	QoQ Change	H1FY25	H1FY26	YoY Change
Revenue from Operations	32.33	24.67	30.32	-6%	23%	57.11	54.98	-4%
Total Income	32.52	25.33	31.00	-5%	22%	57.84	56.33	-3%
Operating Expenses	21.02	17.37	20.70	-2%	19%	37.68	38.07	1%
EBITDA (Excluding OI & EI)	11.31	7.30	9.62	-15%	32%	19.43	16.92	-13%
EBITDA %	35.0%	29.6%	31.7%	-325 bps	215 bps	34.0%	30.8%	-326 bps
Finance Cost	0.43	0.94	1.01	136%	7%	0.74	1.95	162%
Depreciation & Ammortization	2.42	2.42	2.59	7%	7%	4.44	5.01	13%
PBT	8.65	4.60	6.71	-22%	46%	14.98	11.31	-25%
PAT	6.39	3.45	4.93	-23%	43%	11.05	8.37	-24%
EPS (₹)	4.98	2.69	3.86	-22%	43%	8.60	6.55	-24%

About Shree Ganesh Remedies Limited: (SGRL)

Shree Ganesh Remedies Limited is a leading player in the chemical manufacturing industry, specialising in pharmaceutical intermediates and specialty chemicals. With over 19 years of excellence, the company is renowned for its unparalleled expertise in advanced chemical synthesis and complex chemical reactions. Strategically expanding its operations, Shree Ganesh Remedies is focused on innovation through strategic R&D investments and state-of-the-art infrastructure. The company serves over 20 countries, including key markets in the EU and the US, offering tailored solutions to global industry leaders. Committed to sustainable practices, Shree Ganesh Remedies holds multiple accreditations, including ISO certifications and EcoVadis Bronze. With ongoing expansions at its Ankleshwar and Dahej sites and a strategic shift towards complex niche specialty chemicals, the company is well-positioned for future growth and continues to deliver high-quality, custom manufacturing solutions to its clients.

Contact us:

Aditya Patel
Company Secretary
Shree Ganesh Remedies Limited
Email: investors@ganeshremedies.com

Abhishek Mehra
Investor Relations Advisors
TIL Advisors Private Limited
Email: abhishek@theinvestmentlab.in
Mobile No.: +91 95588 14500

Certain statements in this document that are not historical facts are forward looking statements. Such forward looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward- looking statements. Shree Ganesh Remedies Limited will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.